Overview

The Gene Technology Act 2004, enacted by the Australian Parliament, was introduced to address the need for comprehensive regulation of gene technology activities to ensure they do not adversely affect human health and safety or the environment. This legislation established the Office of the Gene Technology Regulator to oversee the assessment and regulation of activities involving genetically modified organisms, including clinical trials of genetically modified organisms for therapeutic purposes. The policy objective of the Act is to balance the potential benefits of gene technology with the need for rigorous safety assessments and public engagement. The Act provides a framework for the assessment of risks associated with gene technology, including the preparation of Risk Assessment and Risk Management Plans for high-risk activities such as clinical trials. This ensures that all stakeholders, including the public, have an opportunity to provide input on the potential impacts of such trials before they are approved.

Scope and Application

The C2022G00620 (Gazette) pertains to the clinical trial application submitted by Medpace Australia Pty Ltd to evaluate the safety and efficacy of a genetically modified chimeric Orthopoxvirus, specifically CF33-hNIS, as a cancer treatment. This legislation applies to Medpace Australia Pty Ltd and the clinical trial participants, who will be recruited from various clinical trial sites and hospitals within Australia. The scope of this legislation is national, as it pertains to the conduct of the clinical trial across multiple sites within the country over a span of 5 years. The legislation also invites submissions from interested parties to contribute to the protection of human health and safety and the environment. Submissions are to be received by 18 August 2022 and should reference DIR 192. The application process is governed by the Gene Technology Act 2000 and its regulations, which establish the framework for the regulation of gene technology in Australia. The Act applies to entities and individuals involved in activities that involve gene technology, including the importation, use, and release of genetically modified organisms. The legislation may be extended or restricted through subordinate instruments, such as regulations or guidelines, which provide additional detail on the specific requirements and procedures for conducting clinical trials of genetically modified organisms in Australia. The Gene Technology Act 2000 and its regulations establish a national framework for the regulation of gene technology in Australia, with the aim of protecting human health and the environment while promoting the safe and responsible use of gene technology. The Act applies to all entities and individuals involved in activities that involve gene technology, including the importation, use, and release of genetically modified organisms. The legislation provides for the assessment and approval of applications for the conduct of clinical trials, as well as the monitoring and enforcement of compliance with the Act and its regulations.

Key Provisions

The main operative sections of the C2022G00620 legislation (Gazette) concern the assessment of an application for a clinical trial of a genetically modified (GM) chimeric Orthopoxvirus (referred to as CF33-hNIS) as a cancer treatment (s1). The application, submitted by Medpace Australia Pty Ltd, seeks approval to conduct this clinical trial in Australia over a period of 5 years, involving up to 18 trial participants receiving multiple doses of the treatment. Section 2 outlines the steps for the Regulator to prepare a Risk Assessment and Risk Management Plan (RARMP) and to invite public submissions before deciding whether to issue the licence for the trial. The obligations and requirements imposed by this Act on the parties and entities it governs include the submission of a detailed application for the clinical trial, which must include comprehensive information about the trial’s objectives, methodology, and potential risks. The Gene Technology Regulator is mandated to review this application thoroughly, prepare a RARMP, and assess the potential impacts on human health and the environment. Furthermore, the Regulator must invite and consider public submissions on the proposed trial, ensuring transparency and public participation in the decision-making process (s3). The legislation also outlines potential consequences for non-compliance with the requirements set forth in the Act. Section 4 specifies that any breaches of the provisions regarding the clinical trial application, the RARMP, or the public consultation process may result in civil or criminal penalties. While the exact penalties are not detailed in the text, breaches could lead to fines, imprisonment, or both, depending on the severity and nature of the offence. The Regulator has the authority to enforce these penalties to ensure compliance with the Act’s provisions.